<DOC>
	<DOCNO>NCT01813292</DOCNO>
	<brief_summary>HIV+ patient consider risk excessive bone fragility . Several factor could contribute : age , male sex , low body mass index ( BMI ) , HIV infection per se , vitamin D deficiency , use tenofovir/a protease inhibitor ( time and/or current use ) . Tenofovir use backbone nucleosides/nucleotides analogue emtricitabine ( FTC ) , license TRUVADA® , without analogue , license VIREAD® . FTC closely resemble lamivudine ( 3TC ) 5-fluorinated , daily intake fluoride ~15 mg. Fluoride induce bone formation stimulate osteoblast , often impaired bone quality . The aim study compare cross-sectional design fluoride level , bone renewal , bone mineral density ( BMD ) HIV+ male patient treat TRUVADA® VIREAD® 60 month . The patient randomly select , match accord age , ethnic origin , BMI .</brief_summary>
	<brief_title>Fluoride Metabolism , Bone Remodelling Mineral Density HIV Patients Treated With Tenofovir +/- Emtricitabine</brief_title>
	<detailed_description>Fluoride metabolism study measurement fluoride blood daily urine , bone remodelling measurement P1NP . Dual X-ray absorptiometry ( DXA ) use determine areal bone mineral density ( aBMD ) lumbar spine , femoral neck distal radius . Volumetric BMD ( v-BMD ) micro-architecture distal radius tibia study use HR-pQCT scan ( Xtreme , Scanco ) .</detailed_description>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>HIV+ patient male patient patient treated tenofovir+emtricitabine ( TRUVADA® ) tenofovir ( VIREAD® ) 60 month . chronic use fluoroquinolones , antifungal agent , steroid malignancy ( current previous ) require chemotherapy radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>male patient</keyword>
	<keyword>treat TRUVADA® VIREAD® 60 month</keyword>
</DOC>